Background: Vogt-Koyanagi-Harada (VKH) disease is a rare, multisystem autoimmune disorder characterized by bilateral granulomatous panuveitis, with or without extraocular manifestations. Although its exact etiology and pathogenesis remain unclear, it is hypothesized to involve T-cell dysregulation targeting melanocyte-containing tissues, including the CNS, eye, ear, and skin. VKH predominantly affects pigmented groups, such as Asians, Hispanics, Indians, Native Americans, and Mediterranean ethnicities, accounting for 7-22.4% of uveitis cases. Retrospective analyses indicate a higher incidence among female patients, with most cases occurring in the second and fifth decades of life. Aim: This case report discusses a patient with probable VKH who exhibited ocular, neurologic, and auditory symptoms typical of the prodromal or acute uveitic phase and responded well to prompt management. Case Presentation: A young female in her late 20s presented with low-grade fever, severe headache, neck pain, and neck stiffness. She had received symptomatic treatment at another hospital without relief. She was empirically started on intravenous antibiotics and dexamethasone for suspected pyogenic meningitis and was discharged upon symptom relief. However, she returned two days later due to symptom recurrence. Ophthalmic examination revealed decreased visual acuity bilaterally (6/24), sluggish pupil reaction, optic disc edema, and bilateral macular serous detachments. Mild vitritis with anterior chamber cells and iris pigment on the anterior lens capsule was noted in the left eye. Systemic examination was unremarkable, except for fine crepitations in the bilateral lower lung fields. Management: Considering VKH disease, the patient was started on intravenous methylprednisolone pulse therapy (1 gram/day) for 3 days, followed by oral steroids and topical steroid drops for the eyes. She was discharged with oral prednisolone and prednisolone acetate 1% eye drops. At follow-up, her vision improved, and there was resolution of papillitis and serous retinal detachments. Conclusions: VKH is a significant cause of bilateral vision loss. This case of probable VKH syndrome underscores the importance of early recognition and aggressive treatment in achieving a favorable visual prognosis.
References
[1]
Rahman, N., Artiaga, J.C.M., Bouras, K., Luis, J., Rees, A. and Westcott, M. (2023) Immunosuppressive Therapy for Vogt-Koyanagi-Harada Disease: A Retrospective Study and Review of Literature. JournalofOphthalmicInflammationandInfection, 13, Article No. 27. https://doi.org/10.1186/s12348-023-00333-6
[2]
Sharma, S., Patil, Y., Garg, R., Rajguru, J., Sirsalmath, M., Bevinakatti, V., etal. (2020) Vogt-Koyanagi-Harada (VKH) Syndrome: A New Perspective for Healthcare Professionals. JournalofFamilyMedicineandPrimaryCare, 9, 31-35. https://doi.org/10.4103/jfmpc.jfmpc_787_19
[3]
Baltmr, A., Lightman, S. and Tomkins-Netzer, O. (2016) Vogt-Koyanagi-Harada Syndrome—Current Perspectives. ClinicalOphthalmology, 10, 2345-2361. https://doi.org/10.2147/opth.s94866
[4]
Fouad, Y., Mekkawy, M., Nowara, M. and Aziz, I. (2023) Clinical and Multimodal Imaging Characteristics of Eyes with Vogt-Koyanagi-Harada Disease: An Egyptian Experience. OmanJournalofOphthalmology, 16, 88-93. https://doi.org/10.4103/ojo.ojo_376_21
[5]
Al-Halafi, A., Dhibi, H.A., Hamade, I.H., Bou Chacra, C.T. and Tabbara, K.F. (2011) The Association of Systemic Disorders with Vogt-Koyanagi-Harada and Sympathetic Ophthalmia. Graefe’sArchiveforClinicalandExperimentalOphthalmology, 249, 1229-1233. https://doi.org/10.1007/s00417-011-1727-4
[6]
Tugal-Tutkun, I., Ozyazgan, Y., Akova, Y.A., Sullu, Y., Akyol, N., Soylu, M., etal. (2006) The Spectrum of Vogt-Koyanagi-Harada Disease in Turkey. InternationalOphthalmology, 27, 117-123. https://doi.org/10.1007/s10792-006-9001-1
[7]
Murthy, S.I., Moreker, M.R., Sangwan, V.S., Khanna, R.C. and Tejwani, S. (2007) The Spectrum of Vogt-Koyanagi-Harada Disease in South India. InternationalOphthalmology, 27, 131-136. https://doi.org/10.1007/s10792-007-9046-9
[8]
Shu, Q., Yang, P., Hou, S., Li, F., Chen, Y., Du, L., etal. (2010) Interleukin-17 Gene Polymorphism Is Associated with Vogt-Koyanagi-Harada Syndrome but Not with Behçet’s Disease in a Chinese Han Population. HumanImmunology, 71, 988-991. https://doi.org/10.1016/j.humimm.2010.06.020
[9]
Chee, S., Jap, A. and Bacsal, K. (2006) Spectrum of Vogt-Koyanagi-Harada Disease in Singapore. InternationalOphthalmology, 27, 137-142. https://doi.org/10.1007/s10792-006-9009-6
[10]
Lavezzo, M.M., Sakata, V.M., Morita, C., Rodriguez, E.E.C., Abdallah, S.F., da Silva, F.T.G., etal. (2016) Vogt-Koyanagi-Harada Disease: Review of a Rare Autoimmune Disease Targeting Antigens of Melanocytes. OrphanetJournalofRareDiseases, 11, Article No. 29. https://doi.org/10.1186/s13023-016-0412-4
[11]
Silpa-Archa, S., Silpa-archa, N., Preble, J.M. and Foster, C.S. (2016) Vogt-Koyanagi-Harada Syndrome: Perspectives for Immunogenetics, Multimodal Imaging, and Therapeutic Options. AutoimmunityReviews, 15, 809-819. https://doi.org/10.1016/j.autrev.2016.04.001
[12]
Moorthy, R.S., Inomata, H. and Rao, N.A. (1995) Vogt-Koyanagi-Harada Syndrome. SurveyofOphthalmology, 39, 265-292. https://doi.org/10.1016/s0039-6257(05)80105-5
Mondkar, S. (2000) Analysis of 87 Cases with Vogt-Koyanagi-Harada Disease. JapaneseJournalofOphthalmology, 44, 296-301. https://doi.org/10.1016/s0021-5155(00)00152-0
[15]
Agrawal, R., Xin, W., Keane, P.A., Chhablani, J. and Agarwal, A. (2016) Optical Coherence Tomography Angiography: A Non-Invasive Tool to Image End-Arterial System. ExpertReviewofMedicalDevices, 13, 519-521. https://doi.org/10.1080/17434440.2016.1186540
[16]
Aggarwal, K., Agarwal, A., Mahajan, S., Invernizzi, A., Mandadi, S.K.R., Singh, R., etal. (2016) The Role of Optical Coherence Tomography Angiography in the Diagnosis and Management of Acute Vogt-Koyanagi-Harada Disease. OcularImmunologyandInflammation, 26, 142-153. https://doi.org/10.1080/09273948.2016.1195001
[17]
Lai, T.Y.Y., Chan, R.P.S., Chan, C.K.M. and Lam, D.S.C. (2008) Effects of the Duration of Initial Oral Corticosteroid Treatment on the Recurrence of Inflammation in Vogt-Koyanagi-Harada Disease. Eye, 23, 543-548. https://doi.org/10.1038/eye.2008.89
[18]
Hosoda, Y., Hayashi, H. and Kuriyama, S. (2015) Posterior Subtenon Triamcinolone Acetonide Injection as a Primary Treatment in Eyes with Acute Vogt-Koyanagi-Harada Disease. BritishJournalofOphthalmology, 99, 1211-1214. https://doi.org/10.1136/bjophthalmol-2014-306244
[19]
Paredes, I., Ahmed, M. and Foster, C.S. (2006) Immunomodulatory Therapy for Vogt-Koyanagi-Harada Patients as First-Line Therapy. OcularImmunologyandInflammation, 14, 87-90. https://doi.org/10.1080/09273940500536766
[20]
Urzua, C.A., Velasquez, V., Sabat, P., Berger, O., Ramirez, S., Goecke, A., etal. (2015) Earlier Immunomodulatory Treatment Is Associated with Better Visual Outcomes in a Subset of Patients with Vogt‐Koyanagi‐Harada Disease. ActaOphthalmologica, 93, e475-e480. https://doi.org/10.1111/aos.12648
[21]
Yeh, S., Huang, Y. and Thomas, J. (2022) Innovations in the Diagnosis and Management of Uveitis: Promising Research to Address Unmet Patient Needs. AnnalsofEyeScience, 7, 1-1. https://doi.org/10.21037/aes-21-54
[22]
Anthony, E., Rajamani, A., Baskaran, P. and Rajendran, A. (2022) Vogt Koyanagi Harada Disease Following a Recent COVID-19 Infection. IndianJournalofOphthalmology, 70, 670-672. https://doi.org/10.4103/ijo.ijo_2550_21
[23]
Yepez, J.B., Murati, F.A., Petitto, M., De Yepez, J., Galue, J.M., Revilla, J., etal. (2021) Vogt-Koyanagi-Harada Disease Following COVID-19 Infection. CaseReportsinOphthalmology, 12, 804-808. https://doi.org/10.1159/000518834